Galera Therapeutics, Inc.
GRTX
$0.02
$0.00-6.62%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -47.57% | -37.31% | -49.35% | -51.82% | -56.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -65.23% | -66.21% | -69.35% | -69.86% | -67.78% |
| Operating Income | 65.23% | 66.21% | 69.35% | 69.86% | 67.78% |
| Income Before Tax | 54.65% | 54.02% | 64.22% | 67.57% | 71.59% |
| Income Tax Expenses | 100.00% | -- | -- | -- | -190.00% |
| Earnings from Continuing Operations | 54.18% | 54.72% | 64.66% | 67.91% | 71.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.18% | 54.72% | 64.66% | 67.91% | 71.85% |
| EBIT | 65.23% | 66.21% | 69.35% | 69.86% | 67.78% |
| EBITDA | 64.84% | 65.94% | 69.19% | 69.73% | 68.17% |
| EPS Basic | 63.86% | 62.87% | 71.66% | 75.57% | 80.99% |
| Normalized Basic EPS | 81.26% | 78.97% | 81.28% | 82.37% | 82.44% |
| EPS Diluted | 63.86% | 62.87% | 71.66% | 75.57% | 80.99% |
| Normalized Diluted EPS | 81.26% | 78.97% | 81.28% | 82.37% | 82.44% |
| Average Basic Shares Outstanding | 61.27% | 47.02% | 33.21% | 22.79% | 43.57% |
| Average Diluted Shares Outstanding | 61.27% | 47.02% | 33.21% | 22.79% | 43.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |